Global Tofacitinib Market, By Strength (5mg, 10mg, 11mg, and 22mg), Drug Class (Antirheumatic, Janus Kinase Inhibitor, and Immunosuppressant), Application (Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, and Others), Demographic (Adult, Pediatric, Geriatric), Dosage Form (Tablet, Solution, Tablet, Extended Release, and Others), Route of Administration (Oral and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2030.
Tofacitinib Market Analysis and Size
Tofacitinib, commonly known as Xeljanz, belongs to the Janus Kinase (JAK) inhibitor class of drugs. It works by inhibiting the activity of Janus kinase enzymes, which are implicated in the inflammation that triggers rheumatoid and psoriatic arthritis symptoms. Tofacitinib is also used to treat moderate to severe ulcerative colitis in individuals who cannot take certain drugs or have failed to respond to other treatments.
Data Bridge Market Research analyses that the tofacitinib market, which was USD 2.34 billion in 2022, would rocket up to USD 5.67 billion by 2030 and is expected to undergo a CAGR of 4.7% during the forecast period of 2023 to 2030. “Antirheumatic” dominates the drug class segment of the market owing to the rise in the incidence of autoimmune disorders among the population.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Tofacitinib Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Strength (5mg, 10mg, 11mg, and 22mg), Drug Class (Antirheumatic, Janus Kinase Inhibitor, and Immunosuppressant), Application (Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, and Others), Demographic (Adult, Pediatric, Geriatric), Dosage Form (Tablet, Solution, Tablet, Extended Release, and Others), Route of Administration (Oral and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa
|
|
Market Players Covered
|
|
|
Market Opportunities
|
|
Market Definition
The medications known as Janus Kinase (JAK) inhibitors include tofacitinib. It is used to treat several autoimmune conditions, most notably ulcerative colitis, psoriatic arthritis, and rheumatoid arthritis.
Tofacitinib Market Dynamics
Drivers
- Increasing prevalence of autoimmune diseases
The increased prevalence of autoimmune illnesses such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis primarily drives the tofacitinib market. The demand for efficient medications such as tofacitinib keeps rising because these conditions impact a sizable section of the world's population.
- Rising geriatric population
As autoimmune illnesses are more common in the elderly, tofacitinib and other drugs used to treat these conditions are projected to be in high demand as the world's elderly population grows.
- Increasing R&D activities
The market for tofacitinib is growing due to ongoing research and development projects in the areas of autoimmune disorders and JAK inhibitors. Tofacitinib can be used to treat various autoimmune diseases, and pharmaceutical companies are exploring this possibility and investing in creating new formulations, which are expected to drive market growth.
Opportunities
- Growing demand for personalized medicine
Personalized medicine and genetics development presents prospects for modifying therapy for specific patients. The treatment plans can be created by identifying the genetic differences and biomarkers linked to the response to tofacitinib. Tofacitinib's effectiveness can be increased using personalized medicine strategies, which pharmaceutical companies can explore through partnerships and collaborations with diagnostic businesses.
- Rising technological advancements and innovation
It is envisaged that improvements in tofacitinib development will result in improved formulations, enhanced drug delivery methods, and novel methodologies. These developments are meant to increase medicine effectiveness, patient compliance, and administration convenience.
- Increasing awareness and early diagnosis
In recent years, autoimmune illnesses have received better diagnoses and more attention. As a result, more individuals are seeking medical care and getting accurate diagnoses, which raises the need for drugs like tofacitinib.
Challenges/ Restraints
- Strict regulations
Drug approval is subject to strict regulatory standards, particularly in terms of safety and efficacy. The time and money required to meet these regulatory requirements and get permits may delay market entry and limit market growth.
- Adverse effects and safety concerns
Tofacitinib has potential adverse effects, similar to any medication, including an increased risk of infections, changes in blood cell counts, abnormalities in liver enzymes, and elevated cholesterol levels. Tofacitinib's acceptance and uptake may be impacted by safety worries and adverse effects, particularly in patient demographics or among more risk-averse healthcare professionals.
- Reimbursement policies
Various nations and healthcare systems have different pricing and reimbursement practices. For pharmaceutical firms, establishing favorable pricing agreements and reimbursement coverage can be difficult, particularly in areas with healthcare systems that are cost-conscious. Pricing pressures may restrict market access and have an impact on tofacitinib usage.
- High Costs of Drugs
Tofacitinib's price and patients' capacity to pay it might be very difficult, especially in areas with insufficient healthcare resources or where reimbursement coverage is restricted. Access and adoption may be hampered by high treatment costs, especially in lower-income communities. For the market to expand, it is crucial to address cost issues and investigate pricing plans that balance accessibility and sustainability.
This tofacitinib market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tofacitinib market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Tofacitinib Market Scope
The tofacitinib market is segmented on the basis of strength, drug class, application, demographic, dosage form, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
Strength
- 5mg
- 10mg
- 11mg
- 22mg
Drug Class
- Antirheumatic
- Antirheumatic disease modifying
- Antirheumatic miscellaneous
- Janus kinase inhibitor
- Immunosuppressant
Application
- Ulcerative colitis
- Rheumatoid arthritis
- Psoriasis
- Others
Demographic
- Adult
- Pediatric
- Geriatric
Dosage form
- Tablet
- Solution
- Extended release
- Others
Route of Administration
- Oral
- Others
End Users
- Hospital
- Clinic
- Others
Distribution channel
- Hospital pharmacy
- Online pharmacy
- Retail pharmacy
Tofacitinib Market Regional Analysis/Insights
Tofacitinib market is analyzed and market size information is provided by the country, strength, drug class, application, demographic, dosage form, route of administration, end-users, and distribution channel as referenced above.
The countries covered in the tofacitinib market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, rest of Middle East and Africa.
North America is expected to dominate the market due to the presence of major key players, high disposable income, and well-developed healthcare infrastructure in this region.
Asia-Pacific is expected to grow during the forecast period of 2023-2030 due to the increasing research and development activities and the rise in the prevalence of rheumatoid arthritis in this region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
Tofacitinib market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Tofacitinib Market Share Analysis
Tofacitinib market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to tofacitinib market research.
Some of the major players operating in the tofacitinib market are:
- Beacon Pharmaceuticals Limited (Bangladesh)
- Pfizer Inc. (U.S.)
- Globe Pharmaceuticals (Egypt)
- Delta Pharma Limited (Bangladesh)
- DRUG INTERNATIONAL LTD. (Bangladesh)
- Mediconlife, Dolphin Pharma (U.S.)
- Lancer Therapeuticals (India)
- Aprazer (India)
- Glenmark Pharmaceuticals Limited (India)
- Sun Pharmaceutical Industries Ltd. (India)
- Shandong Octagon Chemicals Limited (China)
- APINO PHARMA CO., LTD. (China)
- Zydus Cadila (India)
- Beijing Mesochem Technology Co., Ltd. (China)
- Olon S.p.A. (Italy)
- Unichem Laboratories (India)
- Esteve Química (France)
SKU-